Search details
1.
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
Blood
; 134(7): 641-644, 2019 08 15.
Article
in English
| MEDLINE | ID: mdl-31243043
2.
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.
Blood Adv
; 5(9): 2438-2446, 2021 05 11.
Article
in English
| MEDLINE | ID: mdl-33961019
Results
1 -
2
de 2
1
Next >
>>